Objective: Magnetic resonance guided focused ultrasound (MRgFUS) has recently been investigated as a new treatment modality for essential tremor (ET), but the durability of the procedure has not yet been evaluated. This study reports results at a 2-year follow-up after MRgFUS thalamotomy for ET. Methods: A total of 76 patients with moderate-to-severe ET, who had not responded to at least two trials of medical therapy, were enrolled in the original randomized study of unilateral thalamotomy and evaluated using the clinical rating scale for tremor. Sixty-seven of the patients continued in the open-label extension phase of the study with monitoring for 2 years. Nine patients were excluded by 2 years, for example, because of alternative therapy such as deep brain stimulation (n 5 3) or inadequate thermal lesioning (n 5 1). However, all patients in each follow-up period were analyzed. Results: Mean hand tremor score at baseline (19.8 6 4.9; 76 patients) improved by 55% at 6 months (8.6 6 4.5; 75 patients). The improvement in tremor score from baseline was durable at 1 year (53%; 8.9 6 4.8; 70 patients) and at 2 years (56%; 8.8 6 5.0; 67 patients). Similarly, the disability score at baseline (16.4 6 4.5; 76 patients) improved by 64% at 6 months (5.4 6 4.7; 75 patients). This improvement was also sustained at 1 year (5.4 6 5.3; 70 patients) and at 2 years (6.5 6 5.0; 67 patients). Paresthesias and gait disturbances were the most common adverse effects at 1 year-each observed in 10 patients with an additional 5 patients experiencing neurological adverse effects. None of the adverse events worsened over the period of follow-up, and 2 of these resolved. There were no new delayed complications at 2 years. Interpretation: Tremor suppression after MRgFUS thalamotomy for ET is stably maintained at 2 years. Latent or delayed complications do not develop after treatment.
ssential tremor (ET) is one of the most common neurological disorders, with a prevalence of 4.6% in people aged 65 years. 1 Community-based studies have reported at least mild functional impairment in 60% of patients with ET. 1, 2 Medical management, typically with propranolol or primidone, is generally initiated when the tremor begins to interfere with the patient's ability to undertake daily activities, but the effectiveness of drugs for this disorder is limited. 3, 4 Surgery can be considered for patients with disabling, medication-resistant tremor. 4, 5 Stereotactic radiofrequency (RF) thalamotomy and deep brain stimulation (DBS), targeted to the ventralis intermedius nucleus of the thalamus (Vim), have proven effective for treating ET and other tremors. 6, 7 These interventions, although highly effective, have risks associated with an open neurosurgical operation, including intracerebral hemorrhage related to electrode placement, and infections related to surgical incisions and implanted materials. 8, 9 With DBS, there is also the possibility of adverse effects induced by electrical stimulation, longterm hardware breakage or malfunction, and inevitable battery depletion with time. 10, 11 Radiosurgical Vim thalamotomy with gamma knife (GK) has been used as a noninvasive alternative treatment. [12] [13] [14] However, the lack of immediate clinical improvement and the possibility of extension of the lesion beyond the initially targeted region over time inducing permanent neurological deficits have limited the use of this technique. 15 To mitigate these risk and drawbacks, magnetic resonance-guided focused ultrasound (MRgFUS) has emerged as a promising and novel treatment to ablate deep brain target. This incision-free technique creates precise lesions monitored in real time by thermal imagery, without penetration of instruments into the cranial cavity. Furthermore, unlike stereotactic radiosurgery, treatment can be monitored continuously in real time using magnetic resonance (MR) imaging (MRI) and MR thermography. Thus, MRgFUS brain lesioning could prove to be a much safer approach. 16 A prospective, multicenter, randomized trial demonstrated the results 1 year after MRgFUS thalamotomy for ET. 17 In the present study, the durability of tremor relief in patients followed for 2 years after MRgFUS thalamotomy was evaluated to confirm the durability of efficacy and safety of MRgFUS thalamotomy for the treatment of medically refractory ET.
Patients and Methods

Patients
Patients with ET, diagnosed by a neurologist specializing in movement disorders, were enrolled in the study, based on previously described eligibility criteria. 17 Briefly, patients were eligible for inclusion if they had a postural or intention tremor of the hand, which was moderate to severe (defined by a score of 2 on the Clinical Rating Scale for Tremor 18 
Focused Ultrasound Thalamotomy
The details of the MRgFUS thalamotomy procedure have been described previously. 17 Briefly, patients were placed in a stereotactic head frame that was coupled to an MRI-compatible ultrasound transducer. 
Follow-up Evaluations After MRgFUS
Videotaped standardized tremor evaluations obtained at the different centers were assessed by an independent core group of neurologists (Tremor Research Group) for tremor severity and functional impairment using the CRST (at baseline and at 6, 12, and 24 months after treatment). Because the patients' heads were visible, the assessors could determine whether the videotapes were obtained before or after MRgFUS, but they could not determine whether the tapes were from 6, 12, or 24 months after treatment. The hand tremor score (on a scale ranging from 0 to 32, with higher scores indicating more severe tremor) was derived from the CRST, Part A (three items: resting, postural, and action or intention components of hand tremor) and the CRST, Part B (five tasks involving handwriting, drawing, and pouring), in the hand contralateral to the thalamotomy. Functional status was determined with the rating for the disability subsection (Part C) of the CRST. In addition, current and past literature as well as US Food and Drug Administration (FDA) premarket approvals often refer only to the "Tremor component of CRST-A" as the primary endpoint that reflects ET patient outcome following treatment with device (eg, DBS) or medications. To enable a suitable comparison, the "Posture" component of the CRST-A was evaluated in this study. In addition, we have independently assessed the "Action or intention" component of the CRST-A. Adverse effects were sought and ascertained by open-ended and directed questions and by neurological examination.
Statistical Analysis
We analyzed the patient data through 24 months postoperatively to investigate the durability of the treatment effect. The linear mixed-model test and Student's t test were used to evaluate change in the different scores of CRST before and after MRgFUS thalamotomy. Patients who did not attend follow-up for evaluation at 2 years postoperatively were analyzed using the last observation carried forward method. Statistical Package for the Social Sciences (SPSS; ver. 21.0; SPSS, Inc., Chicago, IL) was used for all calculations, with a p value <0.05 considered statistically significant.
Results
Patient Demographics
Mean (6 SD) age and disease duration of the 76 patients were 71.0 6 8.3 (range, 47-89) and 16.8 6 12.3 years, respectively. Most patients were men (68%), righthanded (83%), and white (75%), and most had a family history of tremor (72%). The mean total CRST score for tremor severity was 49.5 (highest possible score, 152). Seventy-six patients were enrolled in the previous prospective trial, 70 patients were included in the analysis at the l-year follow-up, and results from 67 patients were analyzed at the 2-year follow-up. During 2-year followup, 9 patients were either lost to follow-up, had alternative treatment, or voluntarily withdrew from the study; details of these patients are summarized in the Supplementary Table. However, all patients who were evaluated at each follow-up period (6, 12, and 24 months), including patients who ultimately dropped out, were analyzed.
Efficacy on Hand Tremor
For the 76 patients who underwent MRgFUS thalamotomy, the comparative results of pre-and postoperative scores demonstrated that the mean hand tremor score improved by 55% at 6 months (from 19.8 6 4.9 at baseline to 8.6 6 4.5; 75 patients) and by 53% at 12 months (from 19.8 6 4.9 to 8.9 6 4.8; 70 patients). At 2 years, the mean hand tremor score had improved by 56% (8.8 6 5.0; change in the score from baseline to 2 years, 11 points; 95% confidence interval [CI], 7.6-10.0; p < 0.001; 67 patients). At 2 years, 2 patients had no hand tremor (score 0). These results are summarized in Table 1 and schematized in Figure 1A . In addition, the degree of individual symptom improvement of each patient is shown in a Figure 2A . The percentage of symptom improvement in each patient at 2 years after MRgFUS is shown in Figure 3 . At 2 years follow-up, approximately 62% of patients showed tremor scores that improved by greater or equal to 50%.
Functional Improvement
MRgFUS thalamotomy significantly improved the total disability score of Part C of the CRST at 6 months (a 64% reduction in the score from baseline to 6 months [from 16.4 6 4.5 to 5.4 6 4.7]; p < 0.001). This improvement persisted at 12 months (5.4 6 5.3; 70 patients). At 2 years, the mean score sustained its improvement at 60% (6.5 6 5.0; change in the score from baseline to 2 years, 9.9 points; 95% CI, 5.3-7.7; p < 0.001; 67 patients). The results are schematized in Table 1 . The degree of symptom improvement of each patient is shown in Figure 2B .
Change of the Posture Component
MRgFUS thalamotomy had a significant effect on improving postural symptoms of patients with ET. The mean score improved by 69% at 6 months after MRgFUS thalamotomy (from 2.9 6 1.0 at baseline to 0.8 6 1.0). The improvement was maintained at 12 months (0.8 6 1.0; 70 patients). At 2 years, improvement in the mean score persisted, with a 73% reduction observed in mean postural symptom scores (0.9 6 1.0; change in the score from baseline to 2 years, 2.0 points; 95% CI, 0.7-1.1; p < 0.001; 67 patients). The results are schematized in Figure 1C . The data are summarized in Table 1 . The distribution of patients according to severity is shown in Table 2 .
Change of the Action Tremor Score
MRgFUS also showed favorable results for patients' action tremor. The mean action tremor score improved by 59% at 6 months after MRgFUS thalamotomy (from 2.9 6 0.7 at baseline to 1.2 6 0.9). This improvement persisted at 12 months (1.4 6 0.9; 70 patients). At 2 years, the mean score sustained its improvement at 52% (1.4 6 0.9, change in the score from baseline to 2 years, 1.5 points; 95% CI, 1.2-1.6; p < 0.001; 67 patients).
The results are schematized in Figure 1D . The data are summarized in Table 1 . The distribution of patients according to severity is shown in Table 2 .
Adverse Events Associated With MRgFUS
The adverse events associated with MRgFUS were reported in the previous study. 17 Several adverse events occurred at treatment time and continued to 12 months. Those are: paresthesia in 10 subjects; gait disturbance in 10 subjects; taste disturbance in 1 subject; and dysergia, dysmetria, muscle weakness, and dizziness in 1 subject each. All events were mild or moderate. However, none of these events worsened at 2 years follow-up, and 2 of these events resolved (dysergia and paresthesia). An important point to note in the current study is that there were no new complications or adverse events that related to MRgFUS thalamotomy from 12 months to 2 years after MRgFUS.
Discussion
ET hampers activities of daily living and causes social embarrassment and isolation. Medical treatment has limited efficacy and attendant side effects. Surgical treatment options, including DBS, RF thalamotomy, and radiation thalamotomy, are available for patients with medicationresistant tremor. Among these options, several studies have reported that MRgFUS thalamotomy provides substantial symptomatic and functional benefit, with a relatively low rate of adverse effects in patients with severe or medication-refractory ET. 16, 17, 19, 20 However, information (25) 40 (53) 15 (19) 6 months (N 5 75) 16 (21) 34 (46) 18 (24) 7 (9) 0 12 months (N 5 70) 10 (14) 32 (46) 19 (27) 9 (13) 0 24 months (N 5 67) 10 (15) 30 (45) 18 (26) 9 (14) 0 MRgFUS 5 magnetic resonance-guided focused ultrasound.
regarding safety and the durability of tremor relief beyond 1 years following MRgFUS is currently unavailable. The effects of thalamic DBS are long lasting, with a significant reduction in tremor at 2 years and at 6 to 7 years of follow-up. 21 However, gradual loss of tremor control over months or years occurs in some patients with ET who are treated with DBS; at 5-year follow-up, a diminished effect of stimulation was observed in half of the patients. 6 Several explanations have been proposed regarding this phenomenon, including development of tolerance to stimulation, misdiagnosis, and disease progression. 22 In comparison, RF thalamotomy significantly suppressed ET in 86% of patients in the long term; however, tremor recurred in 24% patients up to 5 years postoperatively. 23 Recurrent tremor is frequent after RF thalamotomy, with repeat procedures often necessary to accomplish the desired reduction in tremor. GK thalamotomy for intractable tremor revealed that approximately 80% of patients could expect to receive some clinical benefit from the procedure. 24 However, the effect of this treatment also diminished over time. The cause of the recurrence has been attributed to lesion size, given that several studies have noted that recurrence is nearly always associated with a lesion that is smaller than expected, rather than one that is not ideally located anatomically. 25, 26 However, Chang et al reported that the size of the lesion and degree of symptom improvement were not directly correlated in MRgFUS treatment. 16 These results, which show that the benefit of various treatments for ET can decrease over time, highlight the need for long-term evaluation of the effect of MRgFUS thalamotomy. The current study confirmed the efficacy of MRgFUS thalamotomy in treating medically refractory ET. These data added to the result of randomized trials for MRgFUS thalamotomy with a longer follow-up. Improvements that were observed after 1 month following the thalamotomy were maintained, as confirmed by the assessments at 6, 12, and 24 months after surgery.
Invasive RF thalamotomy is effective, but accompanied by permanent complications in 9% to 23% of patients. 27 For example, the functional outcome of RF thalamotomy was improved by 40% at 24 months after surgery (Fahn-Tolosa-Marin tremor rating scale; from 50.5 at baseline to 30.8), 6 which was consistent with our findings. These researchers also reported that 14 of 34 patients (41%) had complications after thalamotomy (cognitive deterioration in 3 patients; dysarthria in 4; gait disturbance in 8; and arm ataxia in 1) at the 24-month follow-up. 6 Other adverse events reported after invasive RF included intra-or extracerebral hemorrhage, seizures, infection, brain displacement, tension pneumocephalus, and direct injury from probe placement. 27 The beneficial clinical effects of GK thalamotomy are delayed, and it is difficult to accurate localization and size determination of the planned lesion. Furthermore, there is an added risk of delayed serious adverse events secondary to ionizing radiation such as radiation necrosis and collateral trajectory tissue damage. 28 Compared to these other treatment modalities, MRgFUS thalamotomy has many advantages. MRgFUS thalamotomy shows a low rate of adverse events, which are relatively mild in comparison. MRgFUS is noninvasive and does not require general anesthesia, making it applicable to more patients. 29 MRI and thermometry provides real-time intraoperative feedback. Neurological evaluation during treatment also allows for modification of the treatment plan to improve efficacy and safety. To date, five clinical trials using MRgFUS thalamotomy for treatment of ET have been completed and published. The first is an open-labeled, uncontrolled pilot trial by Elias et al. 30 The study was conducted on 15 ET patients. The second study was conducted by Lipsman et al and similarly investigated the use of MRgFUS thalamotomy to treat 4 patients with medically refractive ET. 19 Then, Chang et al reported the outcome of MRgFUS thalamotomy in 11 patients with medication-resistant ET. 16 Fourth, our initial study was the only randomized trial assessing the safety and efficacy of MRgFUS thalamotomy in patients with ET. 17 Recently, MRgFUS thalamotomy outcomes of 18 patients with ET were reported. 20 The follow-up in these studies ranged between 3 and 12 months. Our study is the first prospective trial reporting 2-year outcomes of MRgFUS thalamotomy in a large cohort of patients with ET. There are some important limitations as well as differences and discrepancies between the work we report here and the previous report on this cohort of treated patients. First, the number of reported patients was different; 56 subjects in the previous report were compared to the 20 sham-treated patints, 17 but here we analyzed all 76 patients. Second, the follow-up was versus 2 years here versus 1 year previously. Third, as is characteristic with increasing duration of follow-up, there were patients who dropped out of the study by 2 years. In total, 9 patients, many of whom had unsuccessful treatment or suboptimal benefit, crossed over to an alternative treatment or dropped out or were lost to follow-up at 2 years. The exclusion of nonresponders from the analysis introduces a bias and an overestimate of the benefit in those patients that remained in the study. Nonetheless, our data show that for the majority of patients, the benefits of MRgFUS are immediate and that they endure for at least 2 years. Additional follow-up will be required to determine the incidence of recurrence and the efficacy of MRgFUS over the long term. Notwithstanding these limitations, the findings of our study add to the current literature by showing maintained improvement and acceptable safety of this treatment option for ET at 2 years. Previous studies reported a range of improvement of 35% to 81% in ET severity as assessed by the CRST at the last available follow-up; however, these studies are limited in number of patients and most of them analyzed short-term results. Further work is required to optimize patient selection, improve clinical results, and avoid adverse effects. Determining which patients are most likely to show an optimal response to treatment and who is less likely to respond or show adverse effects is important. In addition, characterizing the topography and size of lesions that cause adverse effects is a priority.
In conclusion, the present study showed that the reduction in tremor and disability in patients with ET after MRgFUS thalamotomy is durable to 2 years after treatment. No new delayed complications that related to MRgFUS thalamotomy occurred from 12 months to 2 years, and some previous adverse effects were further resolved.
